These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of Congenital Toxoplasmosis: Safety of the Sulfadoxine-Pyrimethamine Combination in Children Based on a Method of Causality Assessment. Teil J; Dupont D; Charpiat B; Corvaisier S; Vial T; Leboucher G; Wallon M; Peyron F Pediatr Infect Dis J; 2016 Jun; 35(6):634-8. PubMed ID: 26906163 [TBL] [Abstract][Full Text] [Related]
5. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group. Villena I; Aubert D; Leroux B; Dupouy D; Talmud M; Chemla C; Trenque T; Schmit G; Quereux C; Guenounou M; Pluot M; Bonhomme A; Pinon JM Scand J Infect Dis; 1998; 30(3):295-300. PubMed ID: 9790140 [TBL] [Abstract][Full Text] [Related]
6. [Maternal pancytopenia during antenatal treatment of congenital toxoplasmosis]. Mubiayi N; Coutty N; Detourmignies L; Le Goueff F; Decocq J; Delahousse G Presse Med; 2004 Aug; 33(14 Pt 1):930-3. PubMed ID: 15509046 [TBL] [Abstract][Full Text] [Related]
8. New perspectives in the chemoprophylaxis of toxoplasmosis. Piens MA; Garin JP J Chemother; 1989 Feb; 1(1):46-51. PubMed ID: 2723712 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Trenque T; Simon N; Villena I; Chemla C; Quereux C; Leroux B; Jaussaud R; Rémy G; Dupouy D; Millart H; Pinon JM; Urien S Br J Clin Pharmacol; 2004 Jun; 57(6):735-41. PubMed ID: 15151519 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of children with congenital toxoplasmosis. Berrébi A; Assouline C; Bessières MH; Lathière M; Cassaing S; Minville V; Ayoubi JM Am J Obstet Gynecol; 2010 Dec; 203(6):552.e1-6. PubMed ID: 20633868 [TBL] [Abstract][Full Text] [Related]
11. [Frequency of persistent or transitory serologic negative values in infants with congenital toxoplasmosis. Experience of the Reims Toxoplasmosis Group (1980-1997)]. Chemla C; Villena I; Aubert D; Leroux B; Dupouy D; Pinon JM Presse Med; 2002 Feb; 31(5):232. PubMed ID: 11878142 [No Abstract] [Full Text] [Related]
12. Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. D'Ercole C; Boubli L; Franck J; Casta M; Harle JR; Chagnon C; Cravello L; Leclaire M; Blanc B Prenat Diagn; 1995 Dec; 15(12):1171-5. PubMed ID: 8750300 [TBL] [Abstract][Full Text] [Related]
13. Toxoplasmosis in pregnancy and its transmission to the fetus. Desmonts G; Couvreur J Bull N Y Acad Med; 1974 Feb; 50(2):146-59. PubMed ID: 4521728 [No Abstract] [Full Text] [Related]
14. Human maternofoetal distribution of pyrimethamine-sulphadoxine. Trenque T; Marx C; Quereux C; Leroux B; Dupouy D; Dorangeon PH; Choisy H; Pinon JM Br J Clin Pharmacol; 1998 Feb; 45(2):179-80. PubMed ID: 9491836 [No Abstract] [Full Text] [Related]
15. [Resistance to sulfadoxine-pyrimethamine and pregnancy]. Bourée P Med Sante Trop; 2012; 22(4):371. PubMed ID: 23610785 [No Abstract] [Full Text] [Related]
16. [Limitations of prenatal treatment of congenital toxoplasmosis with a sulfadiazine-pyrimethamine combination]. Boulot P; Pratlong F; Sarda P; Deschamps F; Hedon B; Laffargue F; Viala JL Presse Med; 1990 Mar; 19(12):570. PubMed ID: 2139220 [No Abstract] [Full Text] [Related]
17. [In utero treatment of congenital toxoplasmosis with a pyrimethamine-sulfadiazine combination]. Couvreur J Presse Med; 1991 Jun; 20(24):1136. PubMed ID: 1830148 [No Abstract] [Full Text] [Related]